Categories: Health

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, today announced that Aryeh Batt, Co-Founder and Chief Executive Officer will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 25-26, 2026. The executive team will also be available for one-on-one meetings with investors throughout the conference.

Format: Company Presentation, Live Webcast

Date/Time: Thursday, February 26, 2026, at 8:00 am ET

About Precise Bio

Precise Bio is a clinical-stage regenerative medicine company pioneering tissue engineering using its proprietary 3D-bio-fabrication platform, which integrates cell biology and biomaterials to produce clinical-grade human tissues under GMP conditions. Its lead program, PB-001, is the world’s first bio-printed corneal implant to enter human clinical trials, with additional ophthalmology and advanced tissue programs in development. For more information, visit www.precise-bio.com.

Contact

Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com

GlobeNews Wire

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

48 minutes ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

48 minutes ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

48 minutes ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

49 minutes ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

49 minutes ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

49 minutes ago